Definium Therapeutics
DFTX
93 hedge funds and large institutions have $12.1M invested in Definium Therapeutics in 2023 Q3 according to their latest regulatory filings, with 19 funds opening new positions, 20 increasing their positions, 12 reducing their positions, and 9 closing their positions.
500% more call options, than puts
Call options by funds: $6.01M | Put options by funds: $1M
111% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 9
67% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 12
11% more funds holding
Funds holding: 84 → 93 (+9)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.32% less ownership
Funds ownership: 10.08% → 9.76% (-0.32%)
13% less capital invested
Capital invested by funds: $13.9M → $12.1M (-$1.75M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$797K |
| 2 |
Millennium Management
New York
|
+$785K |
| 3 |
Citigroup
New York
|
+$358K |
| 4 |
Group One Trading
Chicago,
Illinois
|
+$347K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$254K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alyeska Investment Group
Chicago,
Illinois
|
-$2.85M |
| 2 |
BB
Busey Bank
Urbana,
Illinois
|
-$156K |
| 3 |
Renaissance Technologies
New York
|
-$130K |
| 4 |
FCH
Freestone Capital Holdings
Seattle,
Washington
|
-$41K |
| 5 |
BlackRock
New York
|
-$17.4K |
DFTX Hedge Fund Activity: Q3 2023 in Review
93 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Definium Therapeutics (DFTX) for Q3 2023, worth a combined $12.1M — down 13% from $13.9M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new DFTX positions and 9 closed out — a net gain of 10 holders — while 20 added to existing stakes and 12 trimmed.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $797K. The largest seller was Alyeska Investment Group, exiting entirely with an estimated $2.85M sold.
- 93 institutional investors held Definium Therapeutics (DFTX) as of Q3 2023, up from 84 in Q2 2023.
- Funds reported $12.1M of Definium Therapeutics stock for Q3 2023, down 13% quarter-over-quarter.
- 19 funds opened new Definium Therapeutics positions in Q3 2023 and 9 closed out, a net change of +10 holders.
- The largest Definium Therapeutics buyer in Q3 2023 was Susquehanna International Group, an estimated $797K added.
- The largest Definium Therapeutics seller in Q3 2023 was Alyeska Investment Group, an estimated $2.85M sold.
Based on aggregated 13F filings for Q3 2023.